Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyGlobeNewsWire • Wednesday
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical CompanyGlobeNewsWire • 02/26/24
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with CeaproGlobeNewsWire • 02/15/24
AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to ShareholdersBusiness Wire • 12/14/23
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical CompanyGlobeNewsWire • 12/14/23
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate UpdateGlobeNewsWire • 07/13/23
Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight SeriesGlobeNewsWire • 07/05/23
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT TrialGlobeNewsWire • 04/05/23
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)GlobeNewsWire • 03/16/23
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/07/23
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming MilestonesGlobeNewsWire • 01/17/23
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch EventGlobeNewsWire • 01/10/23
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo NordiskGlobeNewsWire • 08/29/22
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent HighlightsGlobeNewsWire • 08/03/22